Mandate

Vinge advises Brummer & Partners in connection with its investment in Saltside Technologies AB

January 29, 2015

Vinge advises Frontier PE (Cayman) L.P., a fond managed by Brummer & Partners, in connection with its investment in Saltside Technologies AB together with Kinnevik and Hillhouse Capital. Saltside Technologies AB operates the leading online horizontal classifieds platforms in three frontier markets through Bikroy (Bangladesh), Ikman (Sri Lanka) and Tonaton (Ghana). All three platforms are market leaders in terms of user base, engagement and monetization. The headquarters are located in Dubai and the group has over 200 employees to date. Frontier PE (Cayman) L.P. is a private equity fund based in Bangladesh and managed by Brummer & Partners, a leading European manager of hedge funds. Brummer & Partners manages 125 billion SEK on behalf of private persons, corporations and institutional investors.

The Vinge team advising Frontier PE (Cayman) L.P. includes partners Christina Kokko and Johan Larsson together with associates Maria Dahlin, Karin Virding and Nicklas Thorgerzon.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024